Direct-acting Antiviral Therapy for Hepatitis C Virus Infection in Hemodialysis Patients
Keywords:
hepatitis C, hemodialysis, direct-acting antivirals, Sofosbuvir®, Daclatasvir®.Abstract
Introduction: Hepatitis C virus infection is common in hemodialysis patients and is considered endemic in these units. The treatment used consisted of pegylated interferon and ribavirin, a combination that presented levels of toxicity and low response. Current drugs bring better results.
Objectives: To determine the efficacy and safety of direct-acting antiviral therapy for hepatitis C virus infection in patients with chronic renal failure on hemodialysis.
Methods: Prospective descriptive study in 19 patients on hemodialysis and with virus C infection, belonging to "Dr. Mario Muñoz Monroy" Teaching General Hospital, from December 2020 to September 2021. All were prescribed for 12 weeks with Sofosbuvir® 400 mg plus Daclatasvir® 60 mg daily. The variables age, sex, liver fibrosis were characterized by the aspartate aminotransferase/platelet index, adverse reactions and viral response 12 weeks after treatment.
Results: Infection predominated in the group of 51 to 60 years (36.84%). Most patients showed an aspartate aminotransferase/platelet ratio ≤ 0.5, corresponding to the absence of significant liver fibrosis (14 patients). A minority of patients reported adverse reactions. No cardiovascular or hepatic toxicity was demonstrated. All patients had an undetectable viral load 12 weeks after treatment.
Conclusions: The combination of Sofosbuvir® with Daclatasvir® for the treatment of hepatitis C virus infection in patients with chronic renal failure undergoing hemodialysis was effective, well tolerated and safe.
Downloads
References
Gómez Gutiérrez C, Chávez Tapia NC, Ponciano Rodríguez G, Uribe M, Méndez Sánchez N. Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. Annal of Hepatology. 2015; 14 (6): 807-814. DOI:.10.5604/16652681.1171751
Moura Neto JA, Gomes Ferraz ML, Lisboa Bittencourt P, Merege Vieira O. Brazilian registry for the elimination of hepatitis C in dialysis units: a call to action for Nephrology. J. Bras. Nefrol.2022;44(1) Disponible en: https://doi.org/10.1590/2175-8239-JBN-2021-0050
Cabezas Niubó EP, Rodríguez Beirís RP, Falagán Andina C, Zamora Cabezas L, Fernández Duharte J. Hepatitis B y C en pacientes en hemodiálisis. MEDISAN. 2010 [citado 3 Nov 2015];14(2). Disponible en: http://bvs.sld.cu/revistas/san/vol_14_2_10/san02210.htm
Santana RR, Martínez Z, Martínez MT, Mato J. Hepatitis C virus present in hemodialysis units from Cuban western region. Rev Cub Meda 2009;48:28-35
Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018 Aug;38(3):181-92.
Saadi G, Kalantar-Zadeh K, Almasio P, Ashuntantang G, Barsoum R, Bruchfeld A, et al. Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations. Afr J Nefrol. 2020;23(1):159-168. PMID: 33354560; PMCID: PMC7751950.
Tartof S, Arduino JM, Wei R, Hsu JW, Rubenstein K, Hu H, et al. The additional impact of chronic kidney disease on cardiovascular outcomes and death among HCV patients. Journal of Hepatology. 2016;64(2):s624 DOI: 10.1016/S0168-8278(16)01161-2
Ridruejo Ezequiel, Galdame3 Omar, Laham Gustavo. Recomendaciones para el tratamiento de la hepatitis crónica por virus c en pacientes con insuficiencia renal crónica, en diálisis o trasplantados renales: indicaciones de tratamiento 2018. Rev. nefrol. dial. traspl. [Internet]. 2019 Mar [citado 2022 Jun 28] ; 39( 1 ): 55-72. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S2346-85482019000100008&lng=es.
Silva M, Ridruejo E, Alonso C. Hepatitis C en pacientes con enfermedad renal crónica: ha llegado la oportunidad de erradicarla. Reseña del manejo en esta población con el advenimiento de las nuevas drogas antivirales. Rev Nefrol Dial trasp.2018;38(1:43-8. Disponible en: https://www.revistarenal.org.ar › article › download
Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 2020;71:686-721. Disponible en: https://doi.org/10.1002/hep.31060
Li M, Chen J, Fang Z.. El régimen basado en sofosbuvir es seguro y efectivo para los pacientes infectados con hepatitis C con enfermedad renal crónica en etapa 4-5: una revisión sistemática y un metanálisis. Virol J.2019;16(34). Disponible en: https://doi.org/10.1186/s12985-019-1140-x
Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. En: Davies DM, editor. Davies’s textbook of adverse drug reactions. New York, USA: Oxford University Press; 1977. p. 44.
Constancio NS, Ferraz MLG, Martins CTB, Kraychete AC, Bitencourt PL, Nascimento MMD. Hepatitis C en Unidades de Hemodiálisis: diagnóstico y abordaje terapéutico. J Bras Nefrol. 2019 Oct-Dic;41(4):539-549. doi: 10.1590/2175-8239-JBN-2018-0177. PMID: 30806444; PMCID: PMC6979573.
Sette LHBC, Lopes EPA, Guedes Dos Anjos NC, Valente LM, Vieira de Oliveira SA, Lucena-Silva N. Alta prevalencia de infección oculta por hepatitis C en pacientes en prediálisis. Mundo J Hepatol. 2019 Enero 27;11(1):109-118. DOI: 10.4254/wjh.v11.i1.109. PMID: 30705723; PMCID: PMC6354127.
Begué Dalmau NM, Frías Chang NV, Méndez Leyva L, Martí Rodríguez LA, Martínez Dalis M. Caracterización de pacientes con hepatitis B y C en hemodiálisis. MEDISAN [Internet].2016 Feb [citado 2022 Jun 26];20(2):161-167. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192016000200005&lng=es.
Rodríguez Fernández L, Delgado Rodríguez E, Blanco Morejón A, Cedeño Díaz D. Caracterización de pacientes con Hepatitis C en el servicio de hemodiálisis.Cienfuegos 2019. Medisur [Internet]. 2021 Abr [citado 2021 Ago 17];19(2):220-227. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2021000200220&lng=es. Epub 30-Abr-2021.
La Rosa Hernández D, Pérez Plasencia R, De la Cruz Quiala B, Suárez Covarrubia E, Hernández de la Rosa O, Sayú Chibá P, et al. Infección por virus de Hepatitis B y C en pacientes hemodializados. Revista Habanera de Ciencias Médicas.2016;15(6):878-889. Disponible en: http://scielo.sld.cu
Saavedra Hernández D, García Verdecia B. Inmunosenescencia: efectos de la edad sobre el sistema inmune. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2014 Dic [citado 2021 Ago 22] ; 30( 4 ): 332-345. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892014000400005&lng=es.
Abraham GM, Obley AJ, Humphrey LL, Qaseem A. World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians. Ann Intern Med 2020.
Patrice Cacoub. Hepatitis C virus infection and chronic kidney disease. Journal of Hepatology.2016;65(1 Suppl):S82–S94. https://doi.org/10.1016/j.jhep.2016.06.011
Fabrizi F, Messa P, Martin P. Impact of hemodialysis therapy on hepatitis C virus infection: a deeper insight. Int J Artif Organs. 2009 Jan;32(1):1-11. DOI: 10.1177/039139880903200101. PMID: 19241358
Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, et al. Longitudinal Analysis of Hepatitis C Virus Replication and Liver Fibrosis Progression in Renal Transplant Recipients. The Journal of Infectious Diseases.2000;181(3):852–858. Disponible en: https://doi.org/10.1086/315355
Hundemer GL, Sise ME, Wisocky J, Ufere N, Friedman LS, Corey KE, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015;47(12):924-9. DOI: 10.3109/23744235.2015.1078908. Epub 2015 Aug 18. PMID: 26365684; PMCID: PMC4732277.
Tamzaourte1 M, Zajjari Y, Berrag S, Adioui T , Aourarh1 A, El Kabbaj D. Safety and efficacy of Sbased regimen in the treatment of hepatitis C virus infection among hemodialysis patients in Morocco. Nephrol.2021;5:077-080. DOI: 10.29328/journal.jcn.1001078
Charatcharoenwitthaya P, Wongpaitoon V, Komolmit P, Sukeepaisarnjaroen W, Tangkijvanich P, Piratvisuth T, et al. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. BMC Gastroenterol. 2020 Mar 5;20(1):47. DOI: 10.1186/s12876-020-01196-0. PMID: 32138687; PMCID: PMC7057522.
Gregory L, Hundemer M, Wisocky J. Use of Sofosbuvir-Based Direct-Acting Antiviral Therapy for Hepatitis C Viral Infection in Patients with Severe Renal Insufficiency. Infect Dis (Lond).2015;47(12):924–929. DOI:10.3109/23744235.2015.1078908
Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver international : official journal of the International Association for the Study of the Liver.2016; 36(6):802–806. Disponible en: https://doi.org/10.1111/liv.13078
Nazario HE, Ndung M, Mod AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver international : official journal of the International Association for the Study of the Liver.2016; 36(6):798–801. Disponible en: https://doi.org/10.1111/liv.13025
Lin T, Wang X, Gao H, Feng Z, Xu L, Ma J, et al. Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease. Blood purification.2020; 49(6):92–699. Disponible en: https://doi.org/10.1159/000499161
Cheema SUR, Rehman MS, Hussain G. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial. BMC Nephrol .2019;20: 438 Disponible en: https://doi.org/10.1186/s12882-019-1631-4
Yeung A, Palmateer NE, Dillon JF, McDonald SA, Smith S , Barclay S4 , et al. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. Journal of Hepatology. 2022; 76:549–557. Disponible en: https://doi.org/10.1016/j.jhep.2021.09.038
Downloads
Published
How to Cite
Issue
Section
License
La Revista Cubana de Higiene y Epidemiologia protege los derechos de autor, y opera con una Licencia Creative Commons 4.0.(Licencia Creative Commons Atribución-No Comercial 4.0 Internacional (CC BY-NC 4.0).Al publicar en ella los autores permiten copiar y redistribuir el material en cualquier medio o formato; remezclar, transformar y crear a partir del material. Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia http://creativecommons.org/licenses/by-nc/4.0/ e indicar si se han realizado cambios. No puede utilizar el material para una finalidad comercial. No hay restricciones adicionales.
Los autores autorizan la publicación de sus escritos conservando los derechos de autoría, y cediendo y transfiriendo a la revista todos los derechos protegidos por las leyes de propiedad intelectual que rigen en Cuba, que implican la edición para difundir la obra.
Los autores podrán establecer acuerdos adicionales para la distribución no exclusiva de la versión de la obra publicada en la revista (por ejemplo, situarla en un repositorio institucional o publicarla en un libro), con el reconocimiento de haber sido publicada primero en esta revista.
